Article info
PDFResponse
Is one narrative enough? Analytical tools should match the problems they address
- Correspondence to Dr Nathan Hodson, Harvard University T H Chan School of Public Health, Boston, MA 02115, USA; n.hodson{at}doctors.org.uk
Citation
Is one narrative enough? Analytical tools should match the problems they address
Publication history
- Received April 15, 2020
- Revised August 5, 2020
- Accepted August 7, 2020
- First published September 8, 2020.
Online issue publication
May 07, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
- Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
- Primary goals, information-giving and men’s understanding: a qualitative study of Australian and UK doctors’ varied communication about PSA screening
- A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening—a qualitative analysis
- Prostate cancer screening and the management of clinically localized disease
- Arrogance of ‘but all you need is a good index finger’: A narrative ethics exploration of lack of universal funding of PSA screening in Canada
- Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening
- Screening for prostate cancer remains controversial
- Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review
- Care of men with cancer-predisposing BRCA variants